CCM
KRYS icon

Coldstream Capital Management’s Krystal Biotech KRYS Stock Holding History

Coldstream Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$243K Buy
939
+16
+2% +$4.26K ﹤0.01% 1041
2025
Q4 		$228K Buy
+923
New +$194K ﹤0.01% 1037
2025
Q2 		– Sell
-556
Closed -$100K – 2297
2025
Q1 		$100K Buy
+556
New +$93.5K ﹤0.01% 1351

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Coldstream Capital Management's KRYS Position: Q1 2026 in Review

Coldstream Capital Management increased its Krystal Biotech (KRYS) stake by 1.7% in Q1 2026, buying an estimated $4.26K and bringing the position to 939 shares worth $243K. The position accounts for ﹤0.01% of the portfolio, ranked #1041.

Coldstream Capital Management first reported a position in KRYS in Q1 2025 and has held it in 3 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Coldstream Capital Management held 939 shares of Krystal Biotech worth $243K as of Q1 2026.
  • Coldstream Capital Management bought 16 Krystal Biotech shares in Q1 2026, an estimated $4.26K.
  • Krystal Biotech made up ﹤0.01% of Coldstream Capital Management's portfolio in Q1 2026, its #1041 holding.
  • Coldstream Capital Management first reported a position in Krystal Biotech in Q1 2025 and has held it in 3 quarters since.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Coldstream Capital Management's 13F filing for Q1 2026, filed 8 May 2026.